GlassScriptPhysician profile
David W Crasto
NPI 1043771306
$14,564.26
in general payments reported to CMS, 2019-2025
30 companies · $2,797 in 2025
The $2,797 reported for 2025 was more than what 83% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $203 · 2021: $2,243 · 2022: $4,834 · 2023: $2,320 · 2024: $2,166 · 2025: $2,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,284.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,283.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,468.38 | 2021-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $3,135.91 | 2020-2025 | Dupixent |
| Genzyme Corporation | $950.75 | 2021-2025 | |
| Janssen Biotech, INC. | $831.91 | 2021-2025 | Tremfya, Xarelto, Remicade |
| Amgen INC. | $733.91 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $731.05 | 2021-2025 | Tremfya |
| Galderma Laboratories, L.P. | $644.03 | 2021-2025 | Nemluvio |
| Lilly USA, LLC | $491.26 | 2021-2025 | Taltz, Ebglyss |
| Incyte Corporation | $458.97 | 2021-2023 | Opzelura |
| Leo Pharma INC. | $417.01 | 2021-2025 | Adbry |
| Sun Pharmaceutical Industries INC. | $335.51 | 2021-2025 | Odomzo, Blu-U |
| Organon LLC | $321.72 | 2025 | Vtama |
| Ucb, INC. | $313.66 | 2022-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $302.19 | 2021-2024 | Arazlo, Jublia, Targretin |
| Arcutis Biotherapeutics, INC. | $221.93 | 2024-2025 | Zoryve |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $210.19 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $192.44 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $144.94 | 2021-2022 | |
| Epi Health, LLC | $97.34 | 2022 | |
| Mayne Pharma Commercial LLC | $94.21 | 2025 | |
| Journey Medical Corporation | $82.93 | 2024-2025 | |
| Dermavant Sciences, INC. | $47.37 | 2023-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $42.16 | 2020 | |
| Almirall LLC | $41.13 | 2024-2025 | Seysara, Klisyri |
| Botanix Sb INC | $34.47 | 2025 | Sofdra |
| Kyowa Kirin, INC. | $27.76 | 2024 | Poteligeo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.45 | 2023 | Spevigo |
| Helsinn Therapeutics (U.S.), INC. | $21.06 | 2021 | |
| Paratek Pharmaceuticals, INC. | $18.90 | 2021 | |
| Coherus Oncology, INC. | $15.69 | 2025 | Loqtorzi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Crasto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.